| Special Interest Guidances/Information | Date Posted |
| Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry – Final Guidance | 30 Jun 2020 |
| Review and Update of Device Establishment Inspection Processes and Standards: Guidance for Industry – Final Guidance | 29 Jun 2020 |
| Development of Anti-Infective Drug Products for the Pediatric Population : Draft Guidance for Industry – Draft Guidance | 29 Jun 2020 |
| Effects of the COVID-19 Public Health Emergency on Formal Meetings and User Fee Applications for Medical Devices – Questions and Answers: Guidance for Industry and Food and Drug Administration Staff – Final Guidance | 22 Jun 2020 |
| Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing: Guidance for Industry – Final Guidance | 19 Jun 2020 |
| Notifying CDRH of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act During the COVID-19 Public Health Emergency (Revised): Guidance for Industry and Food and Drug Administration Staff – Final Guidance | 19 Jun 2020 |
| Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency Guidance for Industry: Guidance for Industry – Final Guidance | 16 Jun 2020 |
| Temporary Policy on Prescription Drug Marketing Act Requirements for Distribution of Drug Samples During the COVID-19 Public Health Emergency: Guidance for Industry – Final Guidance | 08 Jun 2020 |
| Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised): Guidance for Industry and Food and Drug Administration Staff – Final Guidance | 05 Jun 2020 |
| Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements During the COVID-19 Public Health Emergency: Guidance for Industry – Final Guidance | 04 Jun 2020 |
| Institutional Review Board (IRB) Review of Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products During the COVID-19 Public Health Emergency Guidance for IRBs and Clinical Investigators: Guidance for IRBs and Clinical Investigators – Final Guidance | 02 Jun 2020 |
| CVM GFI #240 Proprietary Names for New Animal Drugs – Final Guidance | 01 Jun 2020 |
